prs_id	slug	legacy_id	legacy_model	prswebprefix	trait_code	trait_name	trait_type	description	cohort	cohort_label	method	gwas_source	reference_label	reference_url	snp_count	p_value	pseudo_r2	brier_score	mse	aauc	aauc_ci	effect_metric	top_effect_1	top_effect_1_ci	top_or_1	top_or_1_ci	top_effect_2	top_effect_2_ci	top_or_2	top_or_2_ci	top_effect_5	top_effect_5_ci	top_or_5	top_or_5_ci	top_effect_10	top_effect_10_ci	top_or_10	top_or_10_ci	top_effect_25	top_effect_25_ci	top_or_25	top_or_25_ci	q1_vs_q2_effect	q1_vs_q2_effect_ci	q1_vs_q2_p_value	q1_vs_q3_effect	q1_vs_q3_effect_ci	q1_vs_q3_p_value	q1_vs_q4_effect	q1_vs_q4_effect_ci	q1_vs_q4_p_value	nominally_significant	reversed_effect_warning	underpowered_warning	upload_to_portal	sex	cases	controls	genome_build	tuning_parameter	weights_external_url	weights_url	phewas_download_url	exclusion_download_url	last_updated
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-05-ukb-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-05-ukb-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-05_UKB_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-05)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	124	6.1e-181	0.0571946	0.0813		0.65	0.64-0.661	OR	3.8	3.05-4.75	3.8	3.05-4.75	3.29	2.78-3.89	3.29	2.78-3.89	3.15	2.81-3.54	3.15	2.81-3.54	2.79	2.55-3.06	2.79	2.55-3.06	2.6	2.41-2.81	2.6	2.41-2.81	1.41	1.23-1.62	1.25e-06	2.11	1.86-2.41	1.48e-29	3.93	3.48-4.43	1.32e-109	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-pca-practical-p-5e-05-ukb-20200608	prsweb-phecode185-pca-practical-p-5e-05-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-05_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	Fixed threshold (5e-05)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	1223	2.9e-263	0.0792795	0.0799		0.688	0.678-0.698	OR	5.51	4.52-6.71	5.51	4.52-6.71	4.72	4.06-5.48	4.72	4.06-5.48	4.05	3.64-4.51	4.05	3.64-4.51	3.63	3.33-3.97	3.63	3.33-3.97	3.12	2.89-3.37	3.12	2.89-3.37	1.79	1.54-2.09	1.19e-13	2.84	2.46-3.28	1e-45	5.86	5.12-6.7	8.96e-146	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-06-ukb-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-06-ukb-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-06_UKB_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-06)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	124	6.1e-181	0.0571946	0.0813		0.65	0.64-0.661	OR	3.8	3.05-4.75	3.8	3.05-4.75	3.29	2.78-3.89	3.29	2.78-3.89	3.15	2.81-3.54	3.15	2.81-3.54	2.79	2.55-3.06	2.79	2.55-3.06	2.6	2.41-2.81	2.6	2.41-2.81	1.41	1.23-1.62	1.25e-06	2.11	1.86-2.41	1.48e-29	3.93	3.48-4.43	1.32e-109	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-pca-practical-p-5e-06-ukb-20200608	prsweb-phecode185-pca-practical-p-5e-06-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-06_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	Fixed threshold (5e-06)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	691	3.1e-257	0.0772015	0.0801		0.686	0.676-0.696	OR	5.01	4.1-6.14	5.01	4.1-6.14	4.22	3.61-4.92	4.22	3.61-4.92	3.92	3.52-4.37	3.92	3.52-4.37	3.59	3.28-3.92	3.59	3.28-3.92	3.05	2.83-3.29	3.05	2.83-3.29	1.58	1.35-1.84	4.78e-09	2.73	2.37-3.14	8.42e-45	5.39	4.73-6.14	4.18e-140	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-07-ukb-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-07-ukb-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-07_UKB_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-07)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	123	7.5e-181	0.0571079	0.0813		0.65	0.64-0.66	OR	3.77	3.02-4.7	3.77	3.02-4.7	3.36	2.84-3.97	3.36	2.84-3.97	3.2	2.86-3.59	3.2	2.86-3.59	2.82	2.57-3.09	2.82	2.57-3.09	2.55	2.36-2.75	2.55	2.36-2.75	1.42	1.24-1.64	7.39e-07	2.17	1.91-2.47	1.23e-31	3.91	3.46-4.41	4.21e-108	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-pca-practical-p-5e-07-ukb-20200608	prsweb-phecode185-pca-practical-p-5e-07-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-07_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	Fixed threshold (5e-07)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	492	5.8e-250	0.0759608	0.0802		0.683	0.674-0.693	OR	4.81	3.92-5.91	4.81	3.92-5.91	4.37	3.75-5.1	4.37	3.75-5.1	3.81	3.42-4.25	3.81	3.42-4.25	3.43	3.14-3.75	3.43	3.14-3.75	3.05	2.82-3.29	3.05	2.82-3.29	1.6	1.37-1.86	1.13e-09	2.6	2.26-2.98	5.43e-41	5.27	4.63-6	1.1e-138	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-09-ukb-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-09-ukb-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-09_UKB_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-09)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	86	1e-178	0.0578342	0.0813		0.649	0.638-0.659	OR	4.3	3.48-5.32	4.3	3.48-5.32	3.45	2.93-4.07	3.45	2.93-4.07	3.17	2.83-3.55	3.17	2.83-3.55	2.73	2.49-2.99	2.73	2.49-2.99	2.57	2.38-2.77	2.57	2.38-2.77	1.51	1.31-1.73	7e-09	2.13	1.87-2.43	7.35e-30	3.96	3.51-4.47	2.48e-109	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-pca-practical-p-5e-09-ukb-20200608	prsweb-phecode185-pca-practical-p-5e-09-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-09_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	Fixed threshold (5e-09)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	293	2.2e-239	0.0711127	0.0804		0.678	0.668-0.688	OR	4.51	3.66-5.56	4.51	3.66-5.56	4.21	3.6-4.92	4.21	3.6-4.92	3.64	3.26-4.07	3.64	3.26-4.07	3.36	3.08-3.67	3.36	3.08-3.67	3.06	2.84-3.3	3.06	2.84-3.3	1.62	1.4-1.88	1.87e-10	2.42	2.11-2.78	1.1e-35	5.14	4.52-5.84	1.62e-137	True	False	False	False	Male	3012	29652	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-08-ukb-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-08-ukb-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	UKB	UK Biobank	GWAS Hits	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	117	5.5e-185	0.0584744	0.0813		0.653	0.642-0.662	OR	4.31	3.48-5.33	4.31	3.48-5.33	3.81	3.25-4.47	3.81	3.25-4.47	3.14	2.8-3.52	3.14	2.8-3.52	2.88	2.63-3.16	2.88	2.63-3.16	2.61	2.42-2.82	2.61	2.42-2.82	1.65	1.43-1.9	3.66e-12	2.28	1.99-2.6	1.55e-33	4.28	3.78-4.85	5.53e-116	True	False	False	True	Male	3012	29652	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-p-5e-08-ukb-20200608	prsweb-phecode185-pca-practical-p-5e-08-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	GWAS Hits	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	377	8.8e-246	0.0746154	0.0803		0.681	0.671-0.692	OR	4.85	3.95-5.95	4.85	3.95-5.95	4.07	3.48-4.76	4.07	3.48-4.76	3.79	3.4-4.23	3.79	3.4-4.23	3.5	3.21-3.83	3.5	3.21-3.83	3.05	2.83-3.3	3.05	2.83-3.3	1.74	1.5-2.03	6.33e-13	2.67	2.32-3.07	6.52e-42	5.51	4.82-6.28	2.51e-141	True	False	False	True	Male	3012	29652	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-pt-ukb-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-pt-ukb-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608	P&T	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	UKB	UK Biobank	P&T	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	118	6.6e-186	0.0588082	0.0813		0.653	0.643-0.663	OR	4.34	3.51-5.37	4.34	3.51-5.37	3.87	3.3-4.54	3.87	3.3-4.54	3.08	2.74-3.45	3.08	2.74-3.45	2.87	2.62-3.14	2.87	2.62-3.14	2.63	2.44-2.84	2.63	2.44-2.84	1.57	1.36-1.81	3.07e-10	2.22	1.95-2.54	3.6e-32	4.2	3.71-4.75	6.13e-115	True	False	False	True	Male	3012	29652	GRCh37/hg19	P<=7.94e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-pt-ukb-20200608	prsweb-phecode185-pca-practical-pt-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608	P&T	PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	P&T	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	1023	6.7e-263	0.0802484	0.0799		0.687	0.678-0.698	OR	5.88	4.84-7.13	5.88	4.84-7.13	4.91	4.24-5.7	4.91	4.24-5.7	4.2	3.78-4.68	4.2	3.78-4.68	3.57	3.27-3.9	3.57	3.27-3.9	3.12	2.89-3.36	3.12	2.89-3.36	1.74	1.49-2.02	1.34e-12	2.73	2.37-3.15	2.42e-43	5.67	4.97-6.48	5e-144	True	False	False	True	Male	3012	29652	GRCh37/hg19	P<=2.51e-05	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-prs-cs-ukb-20200608	prsweb-phecode185-pca-practical-prs-cs-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	PRS-CS	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	1120596	1.1485369292536e-308	0.0927567	0.0791		0.705	0.695-0.715	OR	5.58	4.58-6.78	5.58	4.58-6.78	5.11	4.41-5.92	5.11	4.41-5.92	4.55	4.09-5.05	4.55	4.09-5.05	4.05	3.72-4.41	4.05	3.72-4.41	3.47	3.22-3.75	3.47	3.22-3.75	1.77	1.51-2.08	2.36e-12	2.93	2.53-3.4	8.44e-46	6.58	5.73-7.56	7.84e-158	True	False	False	True	Male	3012	29652	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-lassosum-ukb-20200608	prsweb-phecode185-pca-practical-lassosum-ukb-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	UKB	UK Biobank	lassosum	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	178259	1.2e-292	0.0915226	0.0794		0.699	0.69-0.71	OR	5.88	4.85-7.14	5.88	4.85-7.14	4.81	4.14-5.58	4.81	4.14-5.58	4.4	3.96-4.89	4.4	3.96-4.89	3.89	3.57-4.25	3.89	3.57-4.25	3.35	3.11-3.62	3.35	3.11-3.62	1.66	1.42-1.94	2.12e-10	2.8	2.42-3.23	3.9e-44	6.07	5.31-6.95	6.19e-152	True	False	False	True	Male	3012	29652	GRCh37/hg19	s=0.9;Lambda=0.005456	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08